ASH submitted a letter of comments to the National Heart, Lung, and Blood Institute in response to request for information regarding the renewal of the Production Assistance for Cellular Therapies (PACT) program. In the Society's view, the PACT program is a vital component in supporting both promising pre-clinical cellular therapies, and those researchers who continue to advance this highly specialized field. ASH supports the renewal of the PACT program, as well as its expansion into manufacturing products for non-hematological disorders, cell banking, and opening new Centers that bring novel skills. ASH also recommends that the PACT program continue its educational role and work closely with relevant Societies and federal agencies such as the FDA in order to advance the field of cellular therapies in a safe and effective manner.
back to top